<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms - KIVIRID

<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27282

Keywords:

Abstract:

Source: